Wasted time is the enemy of cancer patients.
KIYATEC’s mission is to change the future of cancer care by accurately predicting patient-specific response and non-response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality.
Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and the NCI. We are conducting robust clinical trials to fully demonstrate the power of our approach and earn widespread adoption for a broad portfolio of products predicting response to today’s and tomorrow’s therapies. www.kiyatec.com
KIYATEC’s mission is to change the future of cancer care by accurately predicting patient-specific response and non-response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality.
Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and the NCI. We are conducting robust clinical trials to fully demonstrate the power of our approach and earn widespread adoption for a broad portfolio of products predicting response to today’s and tomorrow’s therapies. www.kiyatec.com
Location: United States, South Carolina, Greenville
Employees: 11-50
Total raised: $25.8M
Founded date: 2005
Investors 4
| Date | Name | Website |
| - | AIM Group | aimgr.com |
| - | Esperante | esperante.... |
| - | Atlanta Te... | angelatlan... |
| - | Collective... | ccventures... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.12.2022 | Series C | $18M | - |
| 15.12.2021 | - | $5M | - |
| 24.05.2012 | - | $2.8M | - |
Mentions in press and media 11
| Date | Title | Description |
| 18.05.2023 | Kiyatec Receives Investment from Brain Cancer Venture Philanthropy Funds | Kiyatec, a Greenville, SC-based functional precision oncology company, received an investment from The Brain Tumor Investment Fund, and Sontag Innovation Fund. The amount of the deal was not disclosed. The company intends to use the funds t... |
| 12.12.2022 | Kiyatec Announces Series C Round with $18 Million | GREENVILLE SC, Kiyatec Inc., announced a closing of its Series C funding round totaling $18 million. >> Click here for more funding data on Kiyatec >> To export Kiyatec funding data to PDF and Excel, click here Kiyatec In... |
| 12.12.2022 | Kiyatec Closes US$18M in Series C | Kiyatec, a Greenville, SC-based precision oncology company, raised US$18M in Series C funding. The round was led by Bruker (Nasdaq: BRKR) with participation from Seae Ventures, VentureSouth, and LabCorp (NYSE: LH). The company intends to us... |
| 21.09.2021 | KIYATEC : Announces Addition of Chief Commercial Officer Stacy Chick to Executive Team | The functional precision oncology company KIYATEC, Inc. announced today the addition of Chief Commercial Officer, Stacy Chick, to their Executive Team. Stacy brings over 30 years of successful life sciences commercialization experience in p... |
| 30.04.2021 | KIYATEC Announces $2,5M Investment | GREENVILLE, SC, KIYATEC has secured a $2.5 million investment from Seae Ventures. >> Click here for more funding data on KIYATEC >> To export KIYATEC funding data to PDF and Excel, click here KIYATEC has secured a $2.5 mi... |
| 01.05.2019 | KIYATEC Announces $3M Initial Closing of Series B2 Preferred Stock Financing | GREENVILLE, S.C.--(BUSINESS WIRE)--KIYATEC, Inc. today announced the initial $3 million closing of the company’s series B2 financing round. The round was led by VentureSouth and included LabCorp® (NYSE: LH). “This validation and confidence ... |
| 01.05.2019 | KIYATEC Announces $3M Initial Closing of Series B2 Preferred Stock Financing | GREENVILLE, S.C.--(BUSINESS WIRE)--KIYATEC, Inc. today announced the initial $3 million closing of the company’s series B2 financing round. The round was led by VentureSouth and included LabCorp® (NYSE: LH). “This validation and confidence ... |
| 24.05.2012 | Cell cultures in 3-D — KIYATEC raises $2.8M for novel testing platform | “The ability to detect a compound that would otherwise fail in clinical trials, before it is used in humans or tested in animals, yields huge benefits,” CEO Matt Gevaert said in a statement. “Patients and doctors can focus more precious tim... |
| 23.05.2012 | KIYATEC Raises Series A Funding | KIYATEC Inc., a Pendleton, SC-based life sciences company, has held the initial close of its Series A funding. The round, whose amount was not revealed, was led by Nexus Medical & Technology Capital and Greenville, SC-based Upstate Caro... |
| - | KIYATEC | “Based on 3D cell culture technology, the company has pioneered a novel “in-hospital startup” model to solve intrinsically complex healthcare problems for the ...” |
Show more